Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases

Cheung, Carmen Ka Man; Law, Kimmy Wan Tung; Law, Alvin Wing Hin; Law, Man Fai; Ho, Rita; Wong, Sunny Hei

doi:10.14218/jcth.2022.00339

Cited by 1 publication

(1 citation statement)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ongoing prevalence of coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) remains a global concern, 1 with 770 million people infected and almost 7 million deaths to date 2 . Patients with dermatomyositis (DM) share similarities in pathogenesis with COVID‐19, 3,4 the pathogenesis and inflammatory episodes of COVID‐19 correlated with the overt pathogenesis of DM 5–9 .…”

Section: Introductionmentioning

confidence: 99%

Clinical and immunological features of COVID‐19 in patients with anti‐MDA5 dermatomyositis during the omicron wave in Chongqing, China

Wu,

Chen,

Zha

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Patients with anti‐melanoma differentiation‐associated gene 5 (anti‐MDA5) dermatomyositis (DM) have a higher risk of coronavirus disease 2019 (COVID‐19) infection. In this longitudinal observational study, we aimed to investigate the clinical and immunological features of these patients after COVID‐19 infection. A total of 73 patients with anti‐MDA5 DM were recruited from the Second Affiliated Hospital of Chongqing Medical University during the Omicron wave epidemic. Clinical data were collected by questionnaire survey and electronic medical records. Blood samples were used to determine the immunity responses. From December 9, 2022 to March 31, 2023, 67 patients were eligible for final analysis; 68.7% of them were infected with COVID‐19. The most common symptoms observed in COVID‐19 were upper respiratory symptoms, most cases were mild or moderate (97.8%). The clinical laboratory indexes were relativity stable in patients after infection (all p > 0.05). Vaccination is not a protective factor against the Omicron infection (odds ratio: 2.69, 95% confidence interval: 0.81–8.93, p = 0.105). Both wildtype (WT) neutralizing antibodies titer and BA.5‐specific immunoglobulin G titer were significantly enhanced after infection (all p < 0.01), which was as high as healthy controls (HCs). The memory B‐cell responses were similar between the patients with anti‐MDA5 DM and HCs (p > 0.05). However, both the WT‐specific CD8+ T cells and CD4+ T cells were reduced in patients with anti‐MDA5 DM (all p < 0.05). In conclusion, patients with anti‐MDA5 DM did not deteriorate the COVID‐19, in turn, COVID‐19 infection did not increase the risk of anti‐MDA5 DM exacerbation. The humoral responses were robust but the cellular responses were weakened after COVID‐19 infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical and immunological features of COVID‐19 in patients with anti‐MDA5 dermatomyositis during the omicron wave in Chongqing, China

Wu,

Chen,

Zha

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases

Abstract: The outbreak of coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality worldwide. Vaccination against coronavirus disease 2019 is a useful weapon to combat the virus. Patients with chronic liver diseases (CLDs), including compensated or decompensated

Cited by 1 publication

References 95 publications

Clinical and immunological features of COVID‐19 in patients with anti‐MDA5 dermatomyositis during the omicron wave in Chongqing, China

Clinical and immunological features of COVID‐19 in patients with anti‐MDA5 dermatomyositis during the omicron wave in Chongqing, China

Contact Info

Product

Resources

About